Tibet Duo Rui Pharmaceutical Hits Day Low Amid Price Pressure at CNY 65.84

Tibet Duo Rui Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 6.51% to reach an intraday low of CNY 65.84. This performance stands in contrast to the China Shanghai Composite, which saw a modest decrease of 0.16% on the same day. Over the past week, Tibet Duo Rui has faced a more pronounced downturn, with a total decline of 8.62%. The one-month performance reflects a substantial drop of 20.98%, indicating ongoing challenges for the company. Despite these recent struggles, the stock has shown resilience over the past year, boasting a remarkable increase of 130.32%, significantly outperforming the broader market index. Financial metrics reveal that the company is currently net-debt free, yet it has reported negative results for the last 17 consecutive quarters. The annual growth rate of net sales has been concerning, declining by 23.17% over the past five years. Additionally, the operating profit has seen a drastic decrease of 242.10% during the same period. With a market capitalization of CNY 1,975 million, Tibet Duo Rui continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.